Biotech | March 12, 2022
BioPharma’s Herceptin biosimilar Phase 3 results positive
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Subscribe To Our Newsletter & Stay Updated
